Ticagrelor vs. Clopidogrel in Post PCI Patients

• Status: Completed
• Trial end date: 2023-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Elective PCI were included in the study. Patients were randomized into two different groups. One group took ASA 80 mg once daily and clopidogrel 75 mg once a day, and the other one took ASA 80 mg once a day and ticagrelor 90 mg twice a day. After six months of close follow-up, patients were asked to give a score to their dyspnea and asked about the major advance cardiovascular events ( MACE)

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shiraz University of Medical Sciences
• Treatments: Clopidogrel; Ticagrelor

Criteria

Inclusion Criteria:

• Experiencing elective percutaneous coronary intervention (PCI).

Exclusion Criteria:

• Patients diagnosed with hypersensitivity to either ticagrelor or clopidogrel

• Active pathological bleeding

• Patients who consumed anticoagulants in the course of their medical therapy